Zegfrovy adds a differentiated oral EGFR exon 20 inhibitor to AstraZeneca's leading lung cancer franchise, directly competing with amivantamab (J&J) in a meaningful niche. The Phase III data supports first-line expansion. The deal is immediately revenue-neutral but strategically positions AZN for mid-term sales upside. Monitor FDA/regulatory reviews and launch assumptions in upcoming earnings calls.
Price Chart
Executive Summary
AstraZeneca signed an exclusive global license agreement for Zegfrovy (sunvozertinib), an oral EGFR inhibitor for non-small cell lung cancer with exon 20 insertion mutations. AstraZeneca pays Dizal Pharmaceutical an upfront $600 million plus up to $900 million in milestones, plus tiered royalties, adding a complementary approved asset to its lung cancer portfolio with positive Phase III data already filed for first-line use.
Key Facts
- AstraZeneca licensed worldwide rights to Zegfrovy (sunvozertinib), an oral irreversible EGFR inhibitor for NSCLC with EGFR exon 20 insertion mutations.
- Upfront payment of $600 million to Dizal, with up to $900 million in development, regulatory, and sales milestones, plus tiered royalties on global sales.
- Zegfrovy is already approved in the US and China for second-line treatment after platinum-based chemotherapy.
- Positive WU-KONG28 Phase III data presented at ASCO 2026 and published in NEJM; sNDA for first-line use submitted to FDA and CDE.
- Breakthrough Therapy Designation granted by both US FDA and China CDE for first-line EGFR exon 20 insertion NSCLC.
- Transaction expected to close in H2 2026 and does not impact 2026 financial guidance.
Financial Impact
Upfront $600M cash outflow plus milestone potential of $900M for a total deal value up to $1.5B before royalties. Royalties are tiered on global sales but rates not disclosed.
Risk Factors
- Execution risk in integrating and commercializing an externally sourced asset
- Competition from Johnson & Johnson's amivantamab (Rybrevant) in the same exon 20 insertion segment
- Milestone and royalty payments reduce net margin if sales underperform
- Regulatory delays or label restrictions for first-line expansion
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-006637 |
| Document: 0001654954-26-006637-index-headers.html | 0001654954-26-006637 |
| Document: 0001654954-26-006637-index.html | 0001654954-26-006637 |
| Document: 0001654954-26-006637.txt | 0001654954-26-006637 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 6-K | $161.85 $168.37 | ▲ +4.03% | ▲ +1.90% | $157.02 (−2.98%) |
Sep 14, 2026 18d ago | 6-K | $163.78 $168.10 | ▼ −2.64% | ▼ −2.53% | $157.02 (+4.13%) |
Sep 8, 2026 24d ago | 6-K | $160.04 $161.85 | ▲ +1.13% | ▲ +2.25% | $157.02 (−1.89%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $157.02 (−3.35%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $157.02 (−3.35%) |
Aug 31, 2026 4w ago | Court Ruling | $162.13 $159.95 | ▲ +1.34% | ▲ +1.20% | $157.02 (+3.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access